The Coalition for Epidemic Preparedness and Innovations: a global partnership

Patrick Florent
Advisor, CEPI
November 29, 2018
Overview

• About CEPI
• Our priorities and investments
What is CEPI?
- Launch: Davos World Economic Forum 2017
- Global coalition of public, private, philanthropic and civil society organisations

Why is CEPI needed?
- Vaccine Industry can’t afford the opportunity cost of developing Vaccines against EID’s
- Vaccines are key intervention to control disease outbreaks

How is CEPI filling the gap?
- To stimulate, finance and coordinate vaccine development for emerging infectious diseases
- Identify priority threats and act when market forces fail to drive needed development
- Move vaccine candidates through late preclinical studies to proof of concept and safety in humans
- Build capabilities for rapid response to unknown threats

CEPI
CEPI: vision, mission, strategic objectives

**Vision**
A world in which epidemics are no longer a threat to humanity

**Mission**
CEPI accelerates the development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks

**Strategic objectives**

- **Preparedness**
  Advance access to safe and effective vaccines against emerging infectious diseases

- **Response**
  Accelerate the research, development and use of vaccines during outbreaks

- **Sustainability**
  Create durable and equitable solutions for outbreak response capacity
How CEPI works

The Board

Investors

Affected countries

Joint coordinating group

CEPI

Scientific Advisory committee

Partners

CEPI
CEPI’s initial priority pathogens

- MERS
- Lassa
- Nipah
- Disease X

(CONFIRMED GLOBAL CASES OF MERS-COV 2012 - 2017)
Seven partnership agreements signed

<table>
<thead>
<tr>
<th>Disease</th>
<th>Lassa and MERS</th>
<th>Lassa and MERS</th>
<th>Lassa</th>
<th>Nipah</th>
<th>Lassa</th>
<th>MERS</th>
<th>Lassa, MERS, and Nipah</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment (up to)</td>
<td>$37.5 M</td>
<td>$56.0</td>
<td>$54.9 M</td>
<td>$25.0 M</td>
<td>$36.0 M</td>
<td>$36.0 M</td>
<td>$19.0M</td>
</tr>
</tbody>
</table>

CEPI
Just in time vaccines: platform technologies

CEPI supports development of vaccine platform technologies that can be rapidly deployed against known and newly emerging pathogens, to limit or prevent future outbreaks.

Projects must demonstrate:

- Safety and immunogenicity

- Validation of the platform using 3 pathogens
  - 2 with known correlates of protection & validated animal model;
  - 1 from the WHO priority pathogen list

- Manufacturing performance
  - 16 weeks for development of vaccine candidate for a new pathogen
  - 6 weeks to clinical benefit after 1st dose
  - 8 weeks to produce 100,000 doses after go-decision

- Funding decisions to be announced Q4, 2018
Sustainability

- The solution will be fully integrated and address the end-to-end supply chain to make vaccines available to affected populations, at an affordable price, when needed.

- Both manufacturing technologies and economic and structural attributes will be needed to sustain the solution over time.